<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02703311</url>
  </required_header>
  <id_info>
    <org_study_id>CB1-3</org_study_id>
    <nct_id>NCT02703311</nct_id>
  </id_info>
  <brief_title>REPAIR - transcatheteR rEPair of mitrAl Insufficiency With caRdioband System</brief_title>
  <acronym>REPAIR</acronym>
  <official_title>REPAIR - transcatheteR rEPair of mitrAl Insufficiency With caRdioband System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Cardioband Transcatheter System (Cardioband) is indicated for the treatment of secondary
      (functional) mitral regurgitation (FMR). The Cardioband is a transcatheter system, deployed
      on the beating heart through a transseptal approach. The Cardioband is deployed along the
      posterior annulus of the mitral valve (MV) and is adjusted under trans-esophageal guidance on
      the beating heart. A CE mark study with 30 subjects has been completed and documented
      reduction of severity of mitral regurgitation (MR) and improvement in 6- minute walk test in
      subjects with moderate to severe MR.

      Study objectives are to test the efficacy of the Cardioband in improving MR and heart failure
      symptoms in patients with symptomatic (New York Heart Association (NYHA) Class III-IVa),
      severe MR in the post-marketing setting, And to evaluate the safety of the Cardioband system
      in the post-marketing setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in severity of MR at 30 days of at least one category on a 0-4 scale.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in distance walked on 6 minute walk test</measure>
    <time_frame>6 months over Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mitral regurgitation severity</measure>
    <time_frame>6, 12, and 24 months over baseline</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in distance walked on 6 minute walk test</measure>
    <time_frame>12, and 24 months over baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in quality of life (QoL) as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>6, 12, and 24 months over baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in New York Heart Association (NYHA) Class</measure>
    <time_frame>6, 12, and 24 months over baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in left ventricular end diastolic volume (LVEDV)</measure>
    <time_frame>6, 12, and 24 months over baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in left ventricular end systolic volume (LVESV)</measure>
    <time_frame>6, 12, and 24 months over baselines</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Device susses</measure>
    <time_frame>Discharge</time_frame>
    <description>Device success is defined as deployment of the Cardioband, with MR reduction at hospital discharge.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient success</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Individual patient success (measured at 6 months and 1 year) defined as device success and the following:
Discharged from index hospitalization
NYHA class improvement by at least 1 level from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days alive and out of hospital</measure>
    <time_frame>12 months</time_frame>
    <description>Days alive and out of hospital due to major cardiovascular events at 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from all-cause mortality and major adverse events (AE)</measure>
    <time_frame>30 days from implant procedure or hospital discharge, whichever is later.</time_frame>
    <description>Freedom from all-cause mortality and major AE is defined as disabling stroke, myocardial infarction (MI) (peri-procedural or spontaneous), renal failure requiring dialysis, life-threatening bleeding, cardiac tamponade and device related cardiac surgical intervention at 30 days from the implant procedure or hospital discharge, whichever is later.</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for urgent/emergent surgical intervention</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Cardiac Valve Annuloplasty</condition>
  <condition>Mitral Valve Annuloplasty</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Cardioband procedure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardioband</intervention_name>
    <description>Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance</description>
    <arm_group_label>Cardioband procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years

          2. Severe (3+ to 4+) secondary Mitral Regurgitation

          3. Symptomatic heart failure (NYHA Class III-IVa) despite guideline directed medical
             therapy including CRT if indicated

          4. The Local Site Heart Team concur that surgery will not be offered as a treatment
             option and that medical therapy is the intended therapy.

          5. Transfemoral access and transseptal deployment of the Cardioband is determined to be
             feasible

          6. Subject is willing and able to provide informed consent and follow protocol

        Exclusion Criteria:

          1. EF &lt; 20%

          2. LVEDD ≥ 70 mm

          3. Heavily calcified annulus or leaflets

          4. Significant CAD requiring revascularization

          5. Active bacterial endocarditis

          6. Any percutaneous coronary, carotid, endovascular intervention or carotid surgery
             within 30 days or any coronary or endovascular surgery within 3 months

          7. Renal insufficiency requiring dialysis

          8. Life expectancy of less than twelve months

          9. Subject is participating in concomitant research studies of investigational products
             that have not reached their primary endpoint

         10. Pulmonary hypertension ≥ 70mmHg at rest

         11. Mitral valve anatomy which may preclude proper device treatment

         12. Right-sided congestive heart failure with echocardiographic evidence of severe right
             ventricular dysfunction and/or severe tricuspid regurgitation

         13. Severe liver disease

         14. Patient is pregnant or lactating

         15. Hypersensitivity to Nickel or Chromium

         16. Clinically significant bleeding diathesis or coagulopathy

         17. History of mitral valve repair

         18. TIA or CVA within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nitza Shoham, PhD</last_name>
    <phone>+972 3 533 5959</phone>
    <phone_ext>806</phone_ext>
    <email>nitza@valtechcardio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bichat hospital</name>
      <address>
        <city>Paris</city>
        <zip>18 75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alec Vahanian, MD</last_name>
      <phone>+33140256735/60</phone>
    </contact>
    <investigator>
      <last_name>Alec Vahanian, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bad Nauheim, Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Walther, Dr. Med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bonn University</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Nickenig, Prof. Dr. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Nef, Prof.Dr.med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrik Treede, Prof.Dr.med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik, St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>5 20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl-Heinz Kuck, Prof</last_name>
      <email>k.kuck@asklepios.com</email>
    </contact>
    <contact_backup>
      <phone>+49401818852305</phone>
    </contact_backup>
    <investigator>
      <last_name>Karl-Heinz Kuck, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Schaefer, Dr. med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Koln, Universitätsklinikum</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Baldus, Prof. Dr. Med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Stephan von Bardeleben, Dr. med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital san raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Azeem Latib, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>November 20, 2016</last_update_submitted>
  <last_update_submitted_qc>November 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Valtech Cardio</keyword>
  <keyword>Cardioband</keyword>
  <keyword>Mitral Valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

